References
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol.90, 262–267 (2006).
- Baudouin C, Pisella P-J, Fillacier K et al. Ocular surface inflammatory changes induced by topical anti-glaucoma drugs: human and animal studies. Ophthalmology106, 556–563 (1999).
- Luo L, Li D, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens31, 186–193 (2005).
- Perry H. Dry eye diagnosis and management in 2004. Curr. Opin. Ophthalmol.15, 299–304 (2004).
- Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol.86, 418–423 (2002).
- Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary-open angle glaucoma. Arch. Ophthalmol.120, 701–713 (2002).
- Kahook MY, Awadallah NS, Noecker RJ. Fixed-combination travoprost 0.004%/timolol 0.5% for open-angle glaucoma or ocular hypertension 1, 25–30 (2006).
- McCue BA, Cason MM, Curtis MA, Faulkner RD, Dahlin DC. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS. J. Pharm. Biomed. Anal.28, 199–208 (2002).
- Waugh J, Jarvis B. Travoprost. Drugs Aging19, 465–471 (2002).
- Al-Jazzaf AM, DeSantis L, Netland PA. Travoprost: a potent ocular hypotensive agent. Drugs Today (Barc).39, 61–74 (2003).
- Toris CB, Zhan GL, Camras CB, McLaughlin MA. Effects of travoprost on aqueous humor dynamics in monkeys. J. Glaucoma14, 70–73 (2005).
- Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci.46, 4159–4163 (2005).
- Lewis RA, Katz G, Weiss MJ et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J. Glaucoma16, 98–103 (2007).
- Peace JH, Gross RL, Smith SE et al. Sustained duration of action of travoprost Z solution. Presented at the American Glaucoma Society. CA, USA, March 2007.
- Alford K, Smith RL, Schlech BA. Microbiological evaluation of Travatan® Z solution: a multi-dose benzalkonium chloride-free ophthalmic solution. Presented at the American Academy of Optometry. CO, USA, December 2006.
- Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without BAK and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv. Ther.23, 511–519 (2006).
- Whitson JT, Cavanagh HD, Lakshman N et al. Assessment of corneal epithelial integrity following acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv. Ther.23, 663–671 (2006).
- Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. Arch. Ophthalmol.112, 1437–1445 (1994).
- Baudouin C, de Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br. J. Ophthalmol.82, 39–42 (1998).
- Malvitte L, Montange T, Vejux A et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br. J. Ophthalmol.91, 29–32 (2007).
- De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldman G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci.40(3), 619–630 (1999).
- Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci.46, 2444–2450 (2005).
Websites
- Abelson MB, Washburn S. The downside of tear preservatives: a working knowledge of preservatives’ long-term effects can help you safeguard your patients. Rev. Ophthalmol. (2002). www.revophth.com/index.asp?page=1_97.htm
- Noecker R. Ophthalmic preservatives: considerations for long-term use in patients with dry eye or glaucoma. Rev. Ophthalmol. (2001) www.revophth.com/2001/june/cme0601_article.htm